{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:20:46Z","timestamp":1762521646349},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T00:00:00Z","timestamp":1388361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Institut Pasteur International Network","award":["ACIP A-02-2010"],"award-info":[{"award-number":["ACIP A-02-2010"]}]},{"name":"Ministry of Public Health of Uruguay"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:sec><jats:label \/><jats:p>The aim of this work was to describe the prevalence of type\u2010specific <jats:italic>Human papillomavirus<\/jats:italic> (HPV) infection in women attending organized cervical cancer screening program in Uruguay. Nine hundred sixty\u2010five liquid cervical cell samples obtained after collection of cervical smears for cytology were assessed for HPV DNA using the Papillocheck system (Greiner BioOne). The overall prevalence of High\u2010Risk (HR) HPV infections was 20.8% and increased from 16.5% in women with normal cytology to 93.3% in HSIL. Prevalence of HPV 16 and\/or 18 was 6.3% and HPV 16 was the most prevalent genotype in normal cytology (3.6%). The five most prevalent genotypes were HPV 16, 31, 51, 56, and 39. The overall prevalence peaked below age 30. This study provides essential baseline information at national level on type\u2010specific HPV prevalence in Uruguay before the introduction of HPV vaccination. It documents the current prevalence of each of the oncogenic genotypes in a population attending cervical cancer screening program, suggesting that at least 64.7% of high risk lesions are potentially preventable by available HPV vaccines, and possibly augmentable if cross\u2010protection against non\u2010vaccine HPV types 31, 33, and 45 is confirmed. <jats:bold><jats:italic>J. Med. Virol. 86:647\u2013652, 2014<\/jats:italic>.<\/jats:bold> \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.23870","type":"journal-article","created":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T09:55:04Z","timestamp":1388397304000},"page":"647-652","source":"Crossref","is-referenced-by-count":12,"title":["Prevalence of type\u2010specific HPV infection in Uruguay"],"prefix":"10.1002","volume":"86","author":[{"given":"Nora","family":"Berois","sequence":"first","affiliation":[{"name":"Glycobiology and Tumor Immunology Laboratory Pasteur Institut of Montevideo Montevideo Uruguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Heard","sequence":"additional","affiliation":[{"name":"National Reference Center of HPV, Pasteur Institut Paris France"},{"name":"Piti\u00e9 Salp\u00eati\u00e8re Hospital, Pierre &amp; Marie Curie University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoraida","family":"Fort","sequence":"additional","affiliation":[{"name":"Preventive Clinics, Ministry of Public Health Montevideo Uruguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Alonso","sequence":"additional","affiliation":[{"name":"Preventive Program of Cervical Cancer, Honorary Comission Against Cancer Montevideo Uruguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adela","family":"Sica","sequence":"additional","affiliation":[{"name":"Preventive Program of Cervical Cancer, Honorary Comission Against Cancer Montevideo Uruguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Moerzinger","sequence":"additional","affiliation":[{"name":"Glycobiology and Tumor Immunology Laboratory Pasteur Institut of Montevideo Montevideo Uruguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Preventive Program of Cervical Cancer, Honorary Comission Against Cancer Montevideo Uruguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Sancho\u2010Garnier","sequence":"additional","affiliation":[{"name":"Department of Prevention, Montpellier University Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Osinaga","sequence":"additional","affiliation":[{"name":"Glycobiology and Tumor Immunology Laboratory Pasteur Institut of Montevideo Montevideo Uruguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Favre","sequence":"additional","affiliation":[{"name":"National Reference Center of HPV, Pasteur Institut Paris France"},{"name":"Genetic Unit, Papillomavirus and Human Cancer Institut Pasteur Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,12,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.02.002"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e318285e753"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/657321"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025493"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67069-9"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70158-5"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70230-8"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.8.813"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-6-21"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22241"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI57149"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27485"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23712"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23479"},{"key":"e_1_2_6_16_1","first-page":"113","volume-title":"Programa de Prevenci\u00f3n del C\u00e1ncer de Cuello Uterino en el Uruguay \u201cDr. Enrique Pouey:\u201d Estrategia y manual de procedimientos","author":"Rodr\u00edguez G","year":"2008"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.108"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22527"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/978-1-4612-2042-8","volume-title":"The system Bethesda for reporting cervical cytology","author":"Solomon D","year":"2004"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2010.12.002"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.23870","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.23870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T14:24:44Z","timestamp":1696602284000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.23870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,30]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1002\/jmv.23870"],"URL":"https:\/\/doi.org\/10.1002\/jmv.23870","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,30]]}}}